Arrivent Biopharma Inc (AVBP) Stock Price, Quote & News

Company Profile

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment o...

Industry: Biotechnology

Sector: Healthcare

Phone: 628 277 4836

Website: arrivent.com

Address:

18 Campus Boulevard, Suite 100, Newtown Square, United States

laaarsas May. 8 at 6:57 PM

$AVBP EMAIL THEM. ASK THEM. DEMAND THE SAP. DEMAND THE MCID AND HOW MANY PFS EVENTS NEEDED TO DO ANALYSIS!!!

0 · Reply

laaarsas May. 7 at 1:31 PM

$AVBP They hide SAP. Effing lunatics. This trial is the riskiest of many.

0 · Reply

Timefortendies77 Apr. 30 at 6:23 PM

$AVBP ArriVent BioPharma (AVBP) defines "mid-2026" as the period spanning approximately May through August 2026.

0 · Reply

judgeyoung2 Apr. 24 at 8:03 PM

$AVBP the way this has been trading + elevated volume suggests it’s coming soon

0 · Reply

justiceforb_85 Apr. 22 at 8:55 PM

$AVBP nice build up to firmonertinib data release. If trial unsuccessful, there still is ALPACCA trial.

0 · Reply

BlackWebX Apr. 21 at 12:32 PM

$AVBP

0 · Reply

laaarsas Apr. 16 at 12:28 PM

$AVBP no one cares fine go lose your money

0 · Reply

laaarsas Apr. 16 at 12:15 PM

$AVBP so weak and scammy not to publish the SAP. Clowns.

0 · Reply

laaarsas Apr. 16 at 12:11 PM

$AVBP they don’t tell us. Where is the SAP. Goddamn it where is it???

0 · Reply

laaarsas Apr. 16 at 12:00 PM

$AVBP fkn scam company not replying to email. HOW MANY EVENTS ARE NEEDED FO READOUT? HOW IS THE STUDY POWERED?? TELL US

0 · Reply

ArriVent Biopharma price target lowered to $43 from $45 at Citi

2026-05-11T21:38:55.000Z - 1 day ago

ArriVent Biopharma reports Q1 EPS (96c), consensus (89c)

May 11, 2026, 4:01 PM EDT - 1 day ago

ArriVent BioPharma Reports First Quarter 2026 Financial Results

2026-05-07T18:45:02.000Z - 5 days ago

ArriVent Biopharma announces FDA clearance of ARR-002 NDA

May 7, 2026, 8:00 AM EDT - 6 days ago

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

2026-04-24T11:06:33.000Z - 19 days ago

Citi ups ArriVent target, opens ‘upside 90-day catalyst watch’

2026-03-23T12:51:34.000Z - 7 weeks ago

ArriVent Biopharma price target raised to $45 from $37 at B. Riley

Mar 17, 2026, 5:00 PM EDT - 2 months ago

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

2026-03-11T20:28:14.000Z - 2 months ago

ArriVent Biopharma assumed with a Buy at BTIG

2026-03-06T12:53:00.000Z - 2 months ago

ArriVent Biopharma price target raised to $50 from $44 at Oppenheimer

2026-03-06T11:15:50.000Z - 2 months ago

ArriVent Biopharma price target raised to $44 from $42 at H.C. Wainwright

2026-03-06T11:00:30.000Z - 2 months ago

ArriVent Biopharma price target raised to $33 from $31 at Citi

Mar 5, 2026, 4:01 PM EST - 2 months ago

ArriVent BioPharma Reports Full Year 2025 Financial Results

2026-02-17T15:25:37.000Z - 3 months ago

Omega takes new stake in Rocket Companies, exits ArriVent Biopharma

ABR AESI APO DMAC ET GEHC MANU

2025-12-22T21:20:44.000Z - 5 months ago

ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald

2025-12-22T13:06:00.000Z - 5 months ago

ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study

Dec 22, 2025, 8:00 AM EST - 5 months ago

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

2025-12-10T11:46:01.000Z - 5 months ago

ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential

2025-12-10T11:40:54.000Z - 5 months ago

ArriVent Biopharma initiated with a Buy at BTIG

2025-11-25T11:25:25.000Z - 6 months ago

ArriVent Biopharma initiated with a Buy at Truist

2025-11-11T19:40:25.000Z - 6 months ago

ArriVent Biopharma management to meet virtually with Clear Street

2025-11-11T11:35:58.000Z - 6 months ago

ArriVent Biopharma price target lowered to $31 from $33 at Citi

2025-11-10T13:05:18.000Z - 6 months ago

ArriVent Biopharma reports Q3 EPS (83c), consensus (78c)

Nov 10, 2025, 8:00 AM EST - 6 months ago

ArriVent BioPharma Reports Third Quarter 2025 Financial Results

2025-11-10T12:45:55.000Z - 6 months ago

ArriVent Biopharma price target raised to $47 from $32 at Clear Street

Sep 22, 2025, 4:05 PM EDT - 8 months ago

ArriVent Appoints Brent S. Rice as Chief Commercial Officer

Sep 9, 2025, 8:00 AM EDT - 8 months ago

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

Aug 11, 2025, 8:00 AM EDT - 9 months ago

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Jul 21, 2025, 8:00 AM EDT - 10 months ago

ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

Jul 1, 2025, 11:15 PM EDT - 11 months ago

ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jul 1, 2025, 4:05 PM EDT - 11 months ago

ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Jun 23, 2025, 8:00 AM EDT - 11 months ago

ArriVent BioPharma Transcript: Study Update

Jun 23, 2025, 7:00 AM EDT - 11 months ago

ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

Jun 20, 2025, 4:05 PM EDT - 11 months ago

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

May 12, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Reports First Quarter 2025 Financial Results

Apr 28, 2025, 8:00 AM EDT - 1 year ago

ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

Mar 3, 2025, 7:00 AM EST - 1 year ago

ArriVent BioPharma Reports Full Year 2024 Financial Results

Jan 21, 2025, 7:00 PM EST - 1 year ago

ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Sep 9, 2024, 12:05 PM EDT - 1 year ago

ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer

Aug 15, 2024, 7:01 AM EDT - 1 year ago

Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

Aug 14, 2024, 4:01 PM EDT - 1 year ago

ArriVent BioPharma Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 1 year ago

ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer

Jun 5, 2024, 7:00 AM EDT - 2 years ago

ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

May 16, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints John Hohneker, M.D., to its Board of Directors

May 8, 2024, 8:00 AM EDT - 2 years ago

ArriVent BioPharma Reports First Quarter 2024 Financial Results

Apr 22, 2024, 4:05 PM EDT - 2 years ago

ArriVent Appoints Kristine Peterson to its Board of Directors

Mar 28, 2024, 8:30 PM EDT - 2 years ago

InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib

Mar 28, 2024, 4:05 PM EDT - 2 years ago

ArriVent BioPharma Reports Full Year 2023 Financial Results

laaarsas May. 8 at 6:57 PM

$AVBP EMAIL THEM. ASK THEM. DEMAND THE SAP. DEMAND THE MCID AND HOW MANY PFS EVENTS NEEDED TO DO ANALYSIS!!!

0 · Reply

laaarsas May. 7 at 1:31 PM

$AVBP They hide SAP. Effing lunatics. This trial is the riskiest of many.

0 · Reply

Timefortendies77 Apr. 30 at 6:23 PM

$AVBP ArriVent BioPharma (AVBP) defines "mid-2026" as the period spanning approximately May through August 2026.

0 · Reply

judgeyoung2 Apr. 24 at 8:03 PM

$AVBP the way this has been trading + elevated volume suggests it’s coming soon

0 · Reply

justiceforb_85 Apr. 22 at 8:55 PM

$AVBP nice build up to firmonertinib data release. If trial unsuccessful, there still is ALPACCA trial.

0 · Reply

BlackWebX Apr. 21 at 12:32 PM

$AVBP

0 · Reply

laaarsas Apr. 16 at 12:28 PM

$AVBP no one cares fine go lose your money

0 · Reply

laaarsas Apr. 16 at 12:15 PM

$AVBP so weak and scammy not to publish the SAP. Clowns.

0 · Reply

laaarsas Apr. 16 at 12:11 PM

$AVBP they don’t tell us. Where is the SAP. Goddamn it where is it???

0 · Reply

laaarsas Apr. 16 at 12:00 PM

$AVBP fkn scam company not replying to email. HOW MANY EVENTS ARE NEEDED FO READOUT? HOW IS THE STUDY POWERED?? TELL US

0 · Reply

Monkey7779192 Apr. 9 at 9:29 AM

$AVBP When did they delay data and why?

2 · Reply

baliosxantos Apr. 8 at 9:07 PM

$AVBP

0 · Reply

SuperGreenToday Apr. 8 at 6:44 PM

$AVBP Share Price: $25.08 Contract Selected: Oct 16, 2026 $25 Calls Buy Zone: $8.50 – $10.50 Target Zone: $14.75 – $18.03 Potential Upside: 64% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

laaarsas Apr. 6 at 8:17 PM

$AVBP I'm starting to lean more towards that firmonertinib might perform closer to sunvozertinib rather than mobocertinib. If that is true, we could see some nice data in a few months. What are your thoughts?

0 · Reply

laaarsas Apr. 6 at 2:57 PM

$AVBP What is the effect size of WU-KONG28?? They only say positive? We must know this!

0 · Reply

laaarsas Apr. 6 at 2:37 PM

$AVBP Yes, we already have class failure from mobocertinib. How can this be salvaged? I don't see it happening.

0 · Reply

laaarsas Apr. 6 at 1:46 PM

$AVBP A huge warning sign is that class-relative mobocertinib failed on PFS vs same control in EXCLAIM-2. Why should Arrivent do any better?

0 · Reply

laaarsas Apr. 6 at 12:28 PM

$AVBP If they replicate results from amivantanab and the PAPILLON, would that be a clear win for the company? A significant jump i share price?

0 · Reply

laaarsas Apr. 6 at 12:09 PM

$AVBP This seems highly interesting so far. Reading up. Hit me with all the negatives. What is the bear case? All risks. Hit me!!

0 · Reply

laaarsas Apr. 6 at 11:01 AM

$AVBP Yo cats what's up?

0 · Reply

SuperGreenToday Apr. 1 at 6:38 AM

$AVBP Share Price: $23.07 Contract Selected: Oct 16, 2026 $25 Calls Buy Zone: $6.50 – $8.03 Target Zone: $12.35 – $15.10 Potential Upside: 79% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	1.35B
Revenue (ttm)	0.00
Net Income (ttm)	-166.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	412,500
Avg Vol	518,444
Day's Range	N/A - N/A
Shares Out	46.37M
Stochastic %K	38%
Beta	1.51
Analysts	Strong Sell
Price Target	$43.92